181 participants
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-06-23
- Start Date:
- 2026-01-13
- Completion:
- 2032-08-02
Conditions
- Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Interventions
- DRUG
No Results Yet